Ministry of Health and Welfare Discloses Pharmaceutical ⁣Expenditure report

‍ South ⁣Korea’s Ministry of Health and Welfare released its first report on economic benefits expenditures within the ⁣pharmaceutical and medical device industries on ‍Feb. 11, aiming ⁣to enhance clarity and⁣ curb illegal rebates.

The report, based on fiscal year 2023 data, includes submissions from 21,789 companies, doubling the participation from the initial 2023 survey, which‍ had 18,099 companies. Analysts attribute this increase to the inclusion of drug promotional business owners (CSOs).

The Health Insurance Review and Assessment Service (HIRA) allows public access to company-specific economic benefit details. However, personal information and detailed clinical ⁤trial data of medical personnel remain protected ‍to safeguard privacy and trade secrets. The disclosure ⁢also avoids⁣ specific product names or beneficiary identification.
‍ ‍

Clinical Trial Support Expenses Disclosed

⁤ The report details the types and amounts of economic benefits provided by companies to medical personnel, along with ‍the number of provisions and cases. Permissible items, as defined by law, include:

• Samples: Minimum quantities of medicines and medical devices for formulation and form verification (labeled as samples, not for patient sales). 1,305 companies provided ⁢14.96 million⁤ units to medical institutions.
• Academic ‍Conference ⁤Support: Covers transportation, ⁤food, lodging, and registration for presenters and chairpersons. 391 companies supported 3,155 ⁤conferences.
• Clinical⁣ Trial support: Includes medical devices and research expenses for clinical trials. 413 companies provided 55.3 billion won and 617 million product units.
• Product Briefing Sessions: Covers transportation, souvenirs (under 50,000 won), lodging, and meals. Total spending reached 232.6 billion won (205.5 billion won for pharmaceuticals, 27.1 billion won for medical devices), averaging 80,000 won per person.
• Post-Commercial Inquiry: Case report expenses under 50,000 won for doctors, dentists, and oriental doctors participating in post-market surveillance (up to 300,000 won for rare diseases or long-term tracking). 101 companies spent 11.63 billion won on 84,000 case reports.
• Payment Condition Discounts: Discounts based on payment⁢ terms (under 0.6% for ⁤3-month terms, 1.2% for 2-month terms, 1.8% for 1-month ⁢terms). 1,867 companies offered 22.18 million discounts.
• Medical Device Performance Checks: Use of medical devices for the minimum time needed to assess performance (1 month). 311 companies provided 857 items and 6,630 devices for pre-purchase ⁢evaluation.

⁢ ⁢ Clinical trials accounted for the largest share (67.6%) of economic benefits, suggesting a focus on ⁤R&D and academic endeavors. Approximately 18.5% of pharmaceutical suppliers and 17.7% of medical device suppliers reported providing economic benefits, indicating participation from many small and medium-sized ‍enterprises.

Legal Risks of Non-Compliance

Failure to comply with regulations regarding economic interest spending reports carries critically important legal risks.⁢ False, missing, or ⁢irrelevant ⁤data can result in imprisonment for up to one year‍ or a⁢ fine of up to⁤ 10 million won for pharmacists and medical device technicians.
⁣

‍ ‍ The government may scrutinize ⁣spending reports for anomalies. Excessive support concentrated on specific medical institutions or personnel, or patterns deviating significantly ⁢from industry averages, could⁤ trigger rebate investigations.

Medical professionals can review⁣ their reported economic benefits and request corrections if needed. Companies should be prepared for inquiries from medical ‍institutions and staff regarding the accuracy of reported support. Failure to respond could lead to complaints or disputes,necessitating accurate information management and rapid response processes.

Compliance Policy Review⁢ Essential

Companies should⁤ re-evaluate existing sales practices and internal controls to proactively prepare for future regulations.While unpublished personal information and some trade secrets are currently excluded from public ⁣disclosure,this may change. Key⁣ areas ⁣for review include economic benefit provisions,⁢ related contract documentation, and compliance policies. Consider the following measures:

• Strengthen Internal⁣ Education and⁢ Guidelines: Provide thorough training on permissible economic benefits for sales and marketing staff, along with in-house guidelines and updates on expenditure reporting.
• Expenditure Report Process Check: Ensure complete collection of required data for expenditure reports, establishing an internal ⁣system for evidence retention and legal preservation.
• Preliminary Monitoring and Self-Audits: Conduct quarterly or semi-annual self-audits to identify and correct abnormal expenditures.
• Beneficiary Request Response procedures: Develop an ⁣internal process for promptly addressing confirmation requests from medical personnel and institutions.
• Future Policy ‍Change Monitoring: Assign duty for monitoring policy ⁤changes from the Ministry of Health and ‍Welfare and other relevant authorities, preparing for potential expansion of guidelines and ⁣public disclosure.

The⁣ expenditure report aims to enhance transparency in the pharmaceutical and medical‍ device sectors,reflecting the government’s commitment ‍to fair trade.Companies ⁢should view⁤ this not as ⁣mere regulation, but as an possibility to strengthen‍ internal controls and improve corporate trust.

⁣ Ultimately,transparent and⁣ legitimate sales activities are crucial for securing a⁣ company’s reputation and long-term sustainability.⁣ Continuous monitoring of government policies and systematic internal compliance management are essential strategies ⁣for the industry.